Clinical Trial: MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) (8 Week, Dose Ranging, Open Label, Randomized Phase 2 With an Extension)

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

---

Official Title: An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With an 18-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholang

Brief Summary: An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)